Fakülteler / Faculties

Permanent URI for this communityhttps://hdl.handle.net/11727/1395

Browse

Filters

2015 - 20202

Settings

search.filters.applied.f.language: search.filters.language.turSubject: search.filters.subject.Diabetes mellitus

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    New Concept Design of an Insulin Pen for Visually Impaired or Blind Diabetius Mellitus Patients
    (2015) Ucar, Tuba; Kocak, Onur; Akpek, Ali; ABI-1247-2020
    Today, diabetes mellitus (diabetes) emerges as an increasingly important health problem because of the problems and frequency that it cause all over the world. Especially type 2 diabetes mellitus is increasing rapidly in all of the developed and developing society with the rapid changes in lifestyle. As of the year 2013, the number of the diabetes patients are 382 million. And this number is expected to reach 592 million increased by %55 in 2035. The main reason of this population growth due to the obesity and physical inactivity is increasing beacuse of urbanization and aging. In our country, according to result of the studies of Turkey diabetes apidemiology (TURDEP-I), type 2 diabetes mellitus %7.2, frequency of impaired glucose tolerance (IGT) %6.7 was found. In the studies of TURDEP-II that is published recently has been seen significantly increase of 2 type diabetes mellitus at age of 20 and over. Uncontrolled diabetes leading to hypoglycemia causes development of complications that affect all systems of the body. (cardiovascular system-eyes-kidney-nervous system) The risk of lower extremity amputation in diabetes patients is 25 times higher than without diabetes. Especaially in developed countries, the most common cause is visual loss and blindness. Under the light of these information, the form of insulin pen was designed that can be used more comfortable for visually handicapped people and blinds
  • No Thumbnail Available
    Item
    Sodium glucose co-transporter 2 inhibitors in heart failure therapy
    (2020) Cavusoglu, Yuksel; Altay, Hakan; Cahn, Avivit; Celik, Ahmet; Demir, Serafettin; Kilicaslan, Baris; Nalbantgil, Sanem; Raz, Itamar; Temizhan, Ahmet; Yildirimturk, Ozlem; Yilmaz, Mehmet Birhan; AAE-1392-2021; 32281958
    Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are a new class of drugs for patients with type 2 diabetes (T2DM) which inhibit urinary glucose reabsorption in the proximal tubule of the nephron and result in glucosuria, natriuresis and diuresis. In large, randomized clinical trials, SGLT-2i have been shown to reduce major cardiovascular (CV) events and heart failure (HF) hospitalizations in patients with T2DM who have atherosclerotic CV disease or CV risk factors. In these trials, SGLT-2i is have their greatest and most consistent effect on reducing the risk of HF hospitalization. The reduction in HF hospitalization was also observed in subgroups of patients with a HF diagnosis at baseline, which raised the possibility of a clinical benefit of SGLT-2i in HF patients, regardless of the presence or absence of T2DM. In very recently published DAPA-HF trial, a SGLT-2i, dapagliflozin treatment on top of standard HF therapy has been shown to have clear clinical benefits in terms of reducing HF hospitalization, CV mortality, all-cause mortality and improving quality of life in HF patients. This compelling evidence suggests that SGLT-2i have a potential to be an effective treatment option in HF, regardless of diabetes. This article provides a comprehensive overview focused on the role of SGLT-2i in the treatment of HF.